Summaries of health policy coverage from major news organizations

On Tuesday, Richmond-based Sangamo Biosciences received approval from FDA to conduct a clinical trial on a new stem cell therapy designed to cure HIV. For the trial, patients with HIV will be given stem cells that have been genetically modified in a way that makes them resistant to HIV infection. The trial is partially funded by the California Institute for Regenerative Medicine.